Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.

Biotechnology

Adverum Biotech

Adverum Biotech's headquarters in Redwood City, CA, United States

Laurent Fischer

Peter Soparkar

Linda Rubinstein

Jason L. Mitchell

Star Seyedkazemi

Kathryn Ask

Andy Ramelmeier

Aneta Ferguson

Romuald Corbau

R. Andrew Ramelmeier

Bill Tan

Dena House

Kishor Peter Soparkar

Mark Lupher

James Scopa

Dawn Svoronos

Rabia Gurses Ozden

Jeffrey Heier

Patrick Machado

C. David Nicholson

The Corporate Affairs team at Adverum Biotech is responsible for managing the company's external and internal communications, fostering investor relations, ensuring regulatory compliance, and guiding strategic business initiatives. This includes advising on legal matters, overseeing financial planning, and strengthening community and stakeholder engagement to support Adverum's mission of developing innovative gene therapies.

Corporate Affairs

The Leadership Team at Adverum Biotech is responsible for guiding the strategic direction and operational excellence of the company. This includes overseeing regulatory affairs, technical operations, and human resources, as well as driving the development and commercialization of innovative gene therapies for ocular and rare diseases. By leveraging their diverse expertise, the team ensures the successful execution of clinical programs and adherence to industry regulations, ultimately working to improve patient outcomes.

Leadership Team

The Scientific Team at Adverum Biotechnologies conducts cutting-edge research and development to advance gene therapy treatments for ocular and rare diseases. They design, evaluate, and optimize therapeutic candidates like ADVM-022 through rigorous scientific analysis and clinical studies. The team also collaborates with medical and technological experts to ensure the efficacy and safety of innovative treatments for conditions such as wet age-related macular degeneration.

Scientific Team

The Clinical Operations team at Adverum Biotech manages and oversees the execution of clinical trials for the company's gene therapy candidates. This includes coordinating clinical development, data management, and contracts to ensure trials are conducted efficiently, comply with regulatory requirements, and generate reliable data to support the development of treatments like ADVM-022 for serious ocular and rare diseases.

Clinical Operations

The Operations Team at Adverum Biotech is responsible for overseeing and managing various critical functions that ensure the seamless progress and delivery of the company's gene therapy projects. This includes program management, supply chain logistics, quality assurance, quality control in lab operations, and facility management. Their combined efforts support the development and clinical evaluation of ADVM-022, aiming to meet the high standards required for treating serious ocular and rare diseases.

Operations Team

The Engineering and IT team at Adverum Biotech comprises experts responsible for developing and maintaining the technology infrastructure that supports the company's gene therapy initiatives. This includes ensuring robust IT end user services, securing IT infrastructure, managing applications essential for research and operations, and providing technical solutions that drive innovative advancements in treatments for ocular and rare diseases.

Adverum Biotech

Org chart

Board & advisors

Teams

Corporate Affairs

Leadership Team

Scientific Team

Clinical Operations

Operations Team

Engineering and IT

Offices

Adverum Biotech

Org chart

Board & advisors

Teams

Corporate Affairs

Leadership Team

Scientific Team

Clinical Operations

Operations Team

Engineering and IT

Offices

Related companies